Old Web
English
Sign In
Acemap
>
authorDetail
>
Mahfuza Jan
Mahfuza Jan
University of Pennsylvania
Janus kinase 2
Progenitor cell
Tyrosine kinase
Immunology
Myeloproliferative Disorders
3
Papers
287
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A Selective, Orally Bioavailable 1,2,4-Triazolo[1,5-A]Pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of Cep-33779.
2012
Journal of Medicinal Chemistry
Benjamin J. Dugan
Diane E. Gingrich
Eugen F. Mesaros
Karen L. Milkiewicz
Matthew A. Curry
Allison L. Zulli
Pawel Dobrzanski
Cynthia Serdikoff
Mahfuza Jan
Thelma S. Angeles
Mark S. Albom
Jennifer L. Mason
Lisa D. Aimone
Sheryl L. Meyer
Zeqi Huang
Kevin J. Wells-Knecht
Mark A. Ator
Bruce Ruggeri
Bruce D. Dorsey
Show All
Source
Cite
Save
Citations (41)
Lestaurtinib (CEP701)is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders
2008
Blood
Elizabeth O. Hexner
Cynthia Serdikoff
Mahfuza Jan
Cezary R. Swider
Candy Robinson
Shi Yang
Thelma S. Angeles
Stephen G. Emerson
Martin Carroll
Bruce Ruggeri
Pawel Dobrzanski
Show All
Source
Cite
Save
Citations (225)
CEP-701 Is a JAK2 Inhibitor Which Attenuates JAK2/STAT5 Signaling Pathway and the Proliferation of Primary Cells from Patients with Myeloproliferative Disorders.
2006
Blood
Pawel Dobrzanski
Elizabeth O. Hexner
Cynthia Serdikoff
Mahfuza Jan
Cezary R. Swider
Candy Robinson
Shi Yang
Thelma Angeles
Stephen G. Emerson
Martin Carroll
Bruce Ruggeri
Show All
Source
Cite
Save
Citations (21)
1